Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  5/30/2013
GSK Investigational Site
mi
from
Durham, NC
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 5/30/2013
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  5/30/2013
GSK Investigational Site
mi
from
Klamath Falls, OR
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 5/30/2013
GSK Investigational Site
mi
from
Klamath Falls, OR
Click here to add this to my saved trials
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  5/30/2013
GSK Investigational Site
mi
from
Charleston, SC
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 5/30/2013
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Los Angeles, CA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Aurora, CO
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Aurora, CO
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Hartford, CT
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Hartford, CT
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Miami, FL
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Gainesville, GA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Gainesville, GA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
St Louis, MO
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
St Louis, MO
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Kalispell, MT
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Kalispell, MT
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Omaha, NE
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Las Vegas, NV
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Brick, NJ
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Brick, NJ
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
High Point, NC
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Cincinatti, OH
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Oklahoma City, OK
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis
mi
from
Portland, OR
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Knoxville, TN
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Dallas, TX
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Abingdon, VA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Abingdon, VA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Spokane, WA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Birmingham, AL
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Los Angeles, CA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Miami, FL
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Gainesville, GA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Gainesville, GA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Iowa City, IA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Louisville, KY
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
New Orleans, LA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Boston, MA
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Ann Arbor, MI
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Rochester, MN
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Tupelo, MS
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Omaha, NE
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Brick, NJ
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Brick, NJ
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Mineola, NY
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Bismark, ND
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Bismark, ND
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  6/17/2013
Novartis Investigative site
mi
from
Dallas, TX
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 6/17/2013
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 34
mi
from
Phoenix, AZ
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 34
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10163
mi
from
Costa Mesa, CA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10163
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
Huntington Beach, CA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10242
mi
from
Rolling Hills Estates, CA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10242
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site
mi
from
San Diego, CA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10179
mi
from
San Jose, CA
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10179
mi
from
San Jose, CA
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 1315
mi
from
Centennial, CO
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 1315
mi
from
Centennial, CO
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10133
mi
from
Denver, CO
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10133
mi
from
Denver, CO
Click here to add this to my saved trials
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated:  6/27/2013
Teva Investigational Site 10128
mi
from
Wheat Ridge, CO
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
Status: Enrolling
Updated: 6/27/2013
Teva Investigational Site 10128
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials